硫酸瑞美吉泮(Rimegepant Sulfate) - 药物靶点：CGRP receptor_在研适应症：急性偏头痛，偏头痛，无先兆偏头痛_专利_临床

概要

基本信息

药物类型

化学药

别名

Rimegepant、Rimegepant Zydis、Rimegepantly

+ [14]

靶点

CGRP receptor

作用方式

拮抗剂

作用机制

CGRP receptor 拮抗剂(降钙素基因相关肽-1型受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Pfizer Inc.Pfizer Canada ULC

Pfizer Australia Pty Ltd.

+ [5]

非在研机构

标新有限公司

权益机构

Royalty Pharma Plc

Weill Cornell Medicine

Bristol Myers Squibb Co.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (2020-02-27),

偏头痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C56H64F4N12O13S

InChIKeySOGUOEZRYKUOHR-CQZKMDJHSA-N

CAS号1374024-48-2

关联

49

项与硫酸瑞美吉泮相关的临床试验

NCT06898047

/ Not yet recruitingN/A

CORRELATE-UK: COnsistency of Response With RimegEpant Oral Lyophilisate in Acute Treatment of migrainE in the United Kingdom

This is a non-interventional, prospective study that will enroll participants with migraine in the United Kingdom currently in use of rimegepant to acutely treat migraine attacks. Participants will be followed up for up to 12 weeks and will complete a daily questionnaire to self-report the consistency of response to rimegepant in acute treatment of migraine.

开始日期2025-09-17

申办/合作机构

Pfizer Inc.

NCT06999252

/ Not yet recruiting临床2期IIT

The Combination of Rimegepant and PD-1 Inhibitor in the Treatment of Liver Metastasis Colorectal Cancer

The goal of this clinical trial is to learn about efficacy of Rimegepant in combination with PD-1 in patients with liver metastasis colorectal cancer. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

开始日期2025-07-01

申办/合作机构

复旦大学

NCT06985342

/ Recruiting临床4期IIT

A Prospective, Open-Label Study Examining the Use of Rimegepant ODT 75 mg or Zavegepant Nasal Spray 10 mg for Acute Treatment of Migraine in the Emergency Department Setting

This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting.
This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.

开始日期2025-06-05

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

100 项与硫酸瑞美吉泮相关的临床结果

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的转化医学

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的专利（医药）

登录后查看更多信息

247

项与硫酸瑞美吉泮相关的文献（医药）

2025-11-01·CLINICAL NEUROLOGY AND NEUROSURGERY

Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon

Article

作者: Alsaffarini, Kareem ; Adel, Fatema ; Suliman, Reem ; El Jadam, Caline ; Pagdato, Beverly ; Alsaadi, Taoufik ; Alkhateri, Athra

INTRODUCTION:

The introduction of calcitonin gene-related peptide (CGRP)-targeted therapies, including monoclonal antibodies (mAbs) and gepants, has revolutionized migraine management by reducing attack frequency, severity, and duration. However, concerns have emerged regarding the potential wearing off effect, where treatment efficacy diminishes before the next scheduled dose. This study evaluates the long-term efficacy and safety of bridging CGRP mAbs with gepants across 16 clinic visits over 24 months of follow-up, to manage the wearing-off phenomenon of mAbs.

METHODS:

This was a retrospective, real-world, exploratory study. The participants included in the study were adult (≥ 18 years) patients diagnosed with migraine. Screening for patients who had received CGRP mAbs for a minimum of 12 months was done. Clinical data was collected from electronic medical records. A total of 439 patients with documented follow-up visits while taking CGRP mAbs were identified. Data was collected from one site, the American Center for Psychiatry and Neurology, Abu Dhabi, UAE.

RESULTS:

Out of the 493 patients, 65 patients had a wear-off effect of CGRP mAbs and were on bridging treatment. Eptinezumab (55.38 %) was the most prescribed CGRP mAb, followed by erenumab (26.15 %) and galcanezumab (18.46 %). Rimegepant (95.38 %) was the primary gepant used for bridging therapy. Weekly headache days (WHD) decreased significantly over the 16 visits, from 4 days at baseline to near zero by visit 16. 41.54 % of patients improved in severity, while 46.15 % remained stable.

CONCLUSION:

These findings strongly suggest the effectiveness of gepants in managing the wearing-off phenomenon across patients on mAbs. They also underscore the importance of individualized treatment approaches. While CGRP-targeted treatments remain highly effective, ongoing research is essential to optimize long-term use and minimize fluctuations in efficacy, ultimately improving patient reported outcomes.

2025-10-28·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-cell sequencing uncovers sensory neuron–mediated CGRP signaling as a driver of sarcoma progression

Article

作者: Gomez-Salazar, Mario ; Birbrair, Alexander ; Zhong, Lingke ; McCarthy, Edward F. ; Guan, Yun ; James, Aaron W. ; Cherief, Masnsen ; Chang, Leslie ; Thottappillil, Neelima ; Ramesh, Sowmya ; Levi, Benjamin ; Xu, Mingxin ; Price, Theodore J. ; Zhu, Manyu ; Archer, Mary ; Uniyal, Ankit ; Bae, Sam ; Morris, Carol D. ; Clemens, Thomas L. ; Xing, Xin ; Qin, Qizhi ; Balaji, Devadutta ; Li, Zhao ; Mittal, Monisha ; Mazhar, Khadijah

Bone pain is a presenting feature of bone cancers such as osteosarcoma (OS), relayed by skeletal-innervating peripheral afferent neurons. Potential functions of tumor-associated sensory neurons in bone cancers beyond pain sensation are unknown. To uncover neural regulatory functions, a chemical-genetic approach in mice with a knock-in allele for TrkA was used to functionally perturb sensory nerve innervation during OS growth and disease progression. TrkA inhibition in transgenic mice led to significant reductions in sarcoma-associated sensory innervation and vascularization, skewed tumor associated macrophage polarization, reduced tumor growth and metastasis, and prolonged overall survival. Single-cell transcriptomics revealed that sarcoma denervation was associated with phenotypic alterations in both OS tumor cells and cells within the tumor microenvironment, and with reduced calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) signaling. Multimodal and multiomics analyses of human OS bone samples further implicated peripheral innervation and neurotrophin signaling in OS tumor biology. Next and in two parallel approaches to inhibit nerve ingrowth, we repurposed FDA-approved bupivacaine liposomes and separately blocked CGRP signaling using FDA-approved Rimegepant. Both strategies led to significant reductions in sarcoma growth, vascularity, and sarcoma-induced hyperalgesia. In sum, TrkA-expressing peripheral neurons positively regulate key aspects of OS progression and sensory neural inhibition disrupts CGRP signaling within the sarcoma microenvironment leading to significantly reduced tumor growth and improved survival. These data suggest that interventions to prevent pathological innervation of OS represent an adjunctive therapy to improve clinical outcomes and survival.

2025-10-01·CEPHALALGIA

Rimegepant for the acute treatment of migraine: A phase 3, multicenter, open-label, long-term safety and effectiveness study in adults from China

Article

作者: Zhong, Qi ; Fountaine, Robert J. ; Zhang, Mingjie ; Han, Xiaoran ; Zhang, Yongbo ; Liu, Jianguang ; Pixton, Glenn C. ; Lu, Zhihong ; Wu, Jin ; Guo, Aihong ; Dong, Hongjuan ; Wang, Hebo ; Zhang, Bei ; Guo, Huailian ; Ma, Liheng ; Yu, Shengyuan ; Yu, Tingmin

Background:

This study evaluated the long-term safety, tolerability and effectiveness of rimegepant, 75 mg orally disintegrating tablet, for the acute treatment of migraine in Chinese adults.

Methods:

This phase 3, multicenter, open-label, single-arm study enrolled Chinese adults with a ≥1 year history of migraine (with or without aura), 6–18 moderate-to-severe migraine attacks/month within three months before a screening visit and at least six migraine days during a 30-day observation phase (OP). After the OP, eligible participants took rimegepant as needed (maximum one tablet per day) at the onset of mild-to-severe migraine attack for a long-term treatment (LTT) of 52 weeks.

Results:

Overall, 240 participants were treated and 208 (86.3%) completed the study. During LTT, 203 (84.6%) participants reported ≥1 treatment-emergent adverse event (TEAE) and 46 (19.2%) reported ≥1 TEAE considered to be rimegepant-related. There were no rimegepant-related serious AEs or rimegepant-related TEAEs that led to treatment interruption or discontinuation. Mean reduction from the OP in monthly migraine days was observed as early as the first four weeks (−1.7; 95% confidence interval = −2.2 to −1.2), with an overall mean reduction of −4.4 (95% confidence interval = −4.9 to −3.9) days across LTT.

Conclusions:

Rimegepant had a favorable long-term safety profile, was well tolerated in Chinese participants, and a reduction in the number of monthly migraine days was observed during the LLT.Trial registration: ClinicalTrials.gov identifier: NCT05371652

275

项与硫酸瑞美吉泮相关的新闻（医药）

2025-11-19

·白癜风专家孟中平

革命性突破！白癜风这些新药将改变千万患者命运

关于白癜风，超过10款创新药物及疗法正在研发道路上快速推进，涵盖JAK抑制剂、单抗注射液、新型小分子药物等多个方向，为中国超过千万患者带来全新希望。治疗困境：复发率高成最大挑战白癜风作为一种获得性色素脱失性皮肤疾病，中国患病率约为0.54%。患者不仅要应对皮肤白斑问题，更承受着沉重的心理负担。传统治疗主要依赖糖皮质激素、光疗等手段，虽然有一定效果，但往往效果有限且容易复发。研究显示，停药后1年内复发率高达30%-50%。特别是对于广泛型白癜风患者，传统治疗效果更加有限，根源在于这些方法无法精准针对白癜风的自身免疫发病机制。机制突破：从免疫到神经的多靶点治疗科学家对白癜风发病机制的理解正在不断深化。最新研究发现，白癜风中存在“感觉神经元-CGRP-cDC1-CD8+T细胞”致病新机制，感觉神经元通过分泌神经肽CGRP调控真皮树突状细胞功能，从而启动并放大针对黑素细胞的自身免疫反应。这一突破性发现为治疗提供了全新靶点，使得针对神经免疫环节的治疗成为可能。同时，针对导致白癜风复发的关键因素——组织驻留记忆T细胞的研究也取得进展，其中IL-15成为重要的治疗靶点。 JAK抑制剂：临床进展显著 JAK抑制剂通过阻断JAK-STAT信号通路，减少炎症因子产生，保护黑色素细胞。目前多款JAK抑制剂展现出治疗潜力：乌帕替尼：2024年被纳入突破性治疗品种，临床数据显示治疗24周时患者面部白斑改善超过35% 利特昔替尼：白癜风适应症正在全球进行III期临床试验，是进展最快的在研新药之一 VC005片：已进入Ⅱ期临床，通过双重通路发挥作用，有望延缓疾病复发单抗注射液：精准靶向的新方向单抗注射液通过精准调节免疫系统，为治疗提供新思路： GR2301注射液：国内首个靶向IL-15单抗 EI-001注射液：抗IFN-γ单抗，可有效阻断黑素细胞损伤 EB06单抗：已获加拿大批准开展II期临床试验小分子药物：创新机制开辟新路径除了传统免疫抑制途径，全新作用机制的小分子药物带来突破： CKBA软膏源自中药乳香活性成分的修饰筛选，采用创新机制靶向T细胞脂肪酸代谢通路。II期临床试验已完成200例患者入组，目前正在进行数据清理分析。瑞美吉泮软膏基于白癜风神经免疫新机制研发，临床试验显示能显著提高白斑复色率，形成了完整的“临床-基础-临床”研究环路。未来展望：个体化治疗新时代白癜风创新药物研发的加速，预示着这一领域正迎来重大变革。治疗模式正从广泛免疫抑制向精准靶向转变，从临时修复向长期稳定发展。随着临床研究的深入推进，首批创新药物预计将在未来几年内陆续上市。白癜风治疗将告别“无药可用”的困境，正式进入精准靶向治疗的新纪元。

突破性疗法临床2期免疫疗法

2025-11-17

·ETPharma

Pfizer launches gene-related peptide for migraine in India

New Delhi: Pfizer India arm has announced the launch of calcitonin gene-related peptide (CGRP) receptor antagonist: Rimegepant for acute treatment of migraine, in adults with a previous insufficient response to triptan. Rimegepant is designed to target migraine’s pathophysiology calcitonin gene-related peptide (CGRP) and delivers rapid and sustained pain relief lasting up to 48 hours post-treatment, while not associated with the risk of medication overuse headaches. It also enables early return to function and sustained relief from most bothersome symptoms. Rimegepant will be available in a 75 mg orally disintegrating tablet (ODT) form, designed for convenient administration without the need for water. “We believe this treatment will help people with migraine manage pain more effectively and reclaim productive days sooner than with currently available options,” said Meenakshi Nevatia, MD, Pfizer Ltd., India By Online Bureau ,

基因疗法上市批准

2025-11-17

目前，超过10种创新药物与疗法正处于研发阶段，覆盖JAK抑制剂、单抗注射液、新型小分子药物等多个方向。这些疗法精准作用于白癜风发病的关键免疫环节，从根源阻断疾病进展，为国内上千万患者带来全新曙光。1 机制揭秘：从免疫异常到神经调控，治疗思路日益多元白癜风的核心发病机制与自身反应性CD8⁺ T细胞异常活化有关，它们错误地攻击黑色素细胞，导致皮肤色素脱失。其中，干扰素-γ（IFN-γ）通过激活JAK-STAT信号通路，在这一过程中起到关键推动作用。近年来，科学研究不断深入。上海交通大学王宏林团队最新揭示了一条全新的致病通路——“感觉神经元-CGRP-cDC1-CD8⁺ T细胞”轴。该机制指出，感觉神经元通过释放神经肽CGRP，调控树突状细胞功能，进而激活并放大针对黑色素细胞的自身免疫反应。这一发现为白癜风治疗开辟了新方向——神经免疫干预成为可能。此外，组织驻留记忆T细胞被证实是白癜风易于复发的“元凶”。它们像潜伏在皮肤的“免疫记忆哨兵”，即使患者临床康复后仍长期存在。白细胞介素-15（IL-15）在该过程中发挥关键作用，使得靶向IL-15的单抗疗法成为研究新热点。 2 JAK抑制剂：多款药物临床进展迅速 JAK抑制剂通过阻断JAK-STAT信号通路，抑制炎症因子产生，从而保护黑色素细胞。目前多款JAK抑制剂在白癜风治疗中展现出良好潜力。乌帕替尼：高选择性JAK1抑制剂，2024年被我国纳入突破性治疗品种，用于成人和12岁以上青少年的非节段型白癜风。临床研究显示，治疗24周后患者面部白斑面积评分指数改善超35%。利特昔替尼：每日一次口服JAK3/TEC激酶双重抑制剂，虽在美国已获批用于斑秃，但其白癜风适应症正在全球推进Ⅲ期临床试验，成为研发进展最快的在研新药之一。 VC005片：由江苏威凯尔研发，作为第二代高选择性JAK1抑制剂，已进入Ⅱ期临床。该药物通过双重通路发挥作用，有望延缓复发，具备用药便捷、可及性强等优势。值得一提的是，芦可替尼乳膏已成为美国FDA批准的首个白癜风外用药物，目前在中国也在积极推进临床与应用进程。 3 单抗疗法：精准靶向带来治疗新希望单抗注射液通过精准调节免疫系统，抑制异常免疫反应对黑色素细胞的攻击，为患者提供新的治疗路径。 GR2301注射液：由重庆智翔金泰研发，是国内首个获批临床、靶向IL-15的白癜风治疗单抗。 EI-001注射液：安立玺荣开发的抗IFN-γ单抗，已完成海外Ⅰ期临床。研究表明，IFN-γ可能通过铁死亡机制直接损伤黑素细胞，而EI-001能有效阻断这一过程并恢复黑色素生成功能。 EB06单抗：获加拿大卫生部批准开展Ⅱ期临床试验，该药特异性结合CXCL10趋化因子。CXCL10在白癜风患者皮肤及血清中高表达，与疾病发生和维持密切相关。目前单抗疗法多处于临床研究阶段，常与光疗、外用药等联合使用，患者需在医生指导下规范治疗。 4 小分子新药：全新机制开辟治疗新赛道除了传统免疫抑制路径，一些具有全新机制的小分子药物也为白癜风治疗带来突破。 CKBA软膏：王宏林团队基于中药乳香活性成分优化而成，具有全球知识产权。该药创新性地靶向T细胞脂肪酸代谢通路，不同于传统免疫抑制机制。由杭州市第三人民医院许爱娥教授主导的Ⅱ期临床已完成全国22个中心共200例患者入组，预计2025年进行数据分析和突破性疗法申请。瑞美吉泮软膏：原本用于偏头痛的CGRP受体拮抗剂，王宏林团队基于神经免疫机制研发其外用剂型。一项57例患者的研究显示，该软膏能有效促进白斑区域复色，构建了“从临床到基础再回归临床”的完整研发闭环。 5 未来展望：精准医疗与全程管理并重白癜风药物研发的蓬勃发展，标志着该领域即将迎来重大转型。治疗策略正从广泛免疫抑制转向精准靶向干预，从短期复色迈向长期稳定。剂型多样化是另一大趋势。除口服制剂外，多个药物开发了外用凝胶等剂型，满足不同部位、不同严重程度患者的个体化需求。在儿童治疗方面，泰恩康的CKBA软膏已启动2–12岁儿童白癜风的研究者发起试验。初步数据显示，该药在儿童各皮损部位均未引发明显药物相关不良反应，有望成为全球首个儿童白癜风创新药物。随着对疾病机制理解的深化，更多创新靶点与疗法不断涌现。从JAK1抑制剂到IL-15单抗，再到神经免疫调节剂，白癜风治疗领域呈现百花齐放之势。预计未来几年，首批创新药物将陆续上市，白癜风治疗将迈入精准靶向新时代。识别下面二维码，咨询白癜风新药渠道

临床2期临床3期突破性疗法

100 项与硫酸瑞美吉泮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸瑞美吉泮	N02C	DB12457

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性偏头痛	韩国	Pfizer Pharmaceuticals Korea Ltd.	2025-03-24
偏头痛	美国	Pfizer Inc.	2020-02-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
无先兆偏头痛	临床3期	美国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	中国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	日本	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	阿根廷	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	加拿大	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	丹麦	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	德国	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	意大利	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	荷兰	Pfizer Inc.	2025-03-11
无先兆偏头痛	临床3期	波兰	Pfizer Inc.	2025-03-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05371652 (Pubmed \| Cephalalgia)	临床3期	偏头痛	240	Rimegepant 75 mg	網襯糧觸壓遞鹹膚鏇製(淵廠觸顧鹹襯鏇範醖壓) = 觸廠鏇廠壓齋壓鏇獵願醖憲艱憲夢鹽繭顧膚艱 (觸糧願範壓願齋鹽憲繭 ) 更多	积极	2025-10-01
NCT05207865 (CTgov)	临床4期	偏头痛 \| 畏光	441	Rimegepant	醖鬱艱網憲觸膚衊繭觸 = 築簾範築鹽鏇鏇構觸觸壓鏇築鏇遞鹽製簾糧醖 (鑰鹽簾齋齋鹽選築夢顧, 獵獵簾齋鹽網艱鬱簾鬱 ~ 壓簾餘廠鏇網淵蓋鹽廠) 更多	-	2025-09-03
NCT04629950 (CTgov)	临床2期	斑块状银屑病	41	Rimegepant (Rimegepant)	鏇廠製範襯壓繭憲鹽齋(糧鑰膚糧糧構鏇糧構製) = 鹹製鑰壓構膚築蓋顧餘鑰餘鏇顧鏇蓋獵遞積顧 (鏇餘廠顧餘網網鏇鬱範, 34.43) 更多	-	2025-07-17
				Placebo (Placebo)	鏇廠製範襯壓繭憲鹽齋(糧鑰膚糧糧構鏇糧構製) = 艱積遞鬱醖齋襯壓膚範鑰餘鏇顧鏇蓋獵遞積顧 (鏇餘廠顧餘網網鏇鬱範, 32.58) 更多
NCT05399485 (CTgov)	临床3期	偏头痛	496	Rimegepant (Rimegepant)	夢鹹壓窪鹽膚餘簾選築(願構淵衊蓋鬱齋獵範壓) = 衊鹹構鏇範齋齋鏇範觸簾齋醖壓醖壓膚鹹窪衊 (壓襯選糧觸襯鏇積艱艱, 醖憲窪窪餘蓋遞齋願積 ~ 簾遞膚鹹蓋願蓋網簾製) 更多	-	2025-07-14
				Placebo (Placebo)	夢鹹壓窪鹽膚餘簾選築(願構淵衊蓋鬱齋獵範壓) = 積獵遞衊鬱製範築淵糧簾齋醖壓醖壓膚鹹窪衊 (壓襯選糧觸襯鏇積艱艱, 繭窪遞積蓋鑰鹽鏇鏇願 ~ 蓋網網窪襯鬱夢餘襯鏇) 更多
NCT03266588 (Pubmed \| Cephalalgia)	临床2/3期	-	-	Triptan-naïve participants	築選範選廠繭壓艱夢廠(選積繭餘網選築壓窪顧) = 鬱觸鹹鑰衊艱淵願廠窪願網鬱糧網遞積淵顧鹽 (簾繭夢鑰鏇壓繭顧構夢 ) 更多	积极	2025-07-01
				Triptan-using participants	築選範選廠繭壓艱夢廠(選積繭餘網選築壓窪顧) = 遞窪淵築壓築構餘鑰夢願網鬱糧網遞積淵顧鹽 (簾繭夢鑰鏇壓繭顧構夢 ) 更多
NCT03732638 (Pubmed \| Headache)	临床2/3期	偏头痛	603	Rimegepant 75 mg EOD	鬱構憲壓蓋構憲選構選(製遞鹹廠餘鹹獵淵構鹽) = n = 4, 0.7% 憲淵艱餘窪蓋窪襯廠獵 (壓遞網齋壓築範繭糧鏇 ) 更多	积极	2025-06-30
NCT05399459 (Pubmed \| Headache)	临床2/3期	偏头痛	706	Rimegepant 25 mg	鏇鹹築蓋廠簾遞鹽窪製(襯襯蓋艱製鹽鬱獵獵餘) = 獵築憲鑰範蓋廠網範壓簾願窪廠膚繭餘蓋鹹築 (窪蓋憲鑰醖遞構繭壓構 )	积极	2025-06-30
				Rimegepant 75 mg	鏇鹹築蓋廠簾遞鹽窪製(襯襯蓋艱製鹽鬱獵獵餘) = 襯餘鏇觸鹹鏇獵積憲鏇簾願窪廠膚繭餘蓋鹹築 (窪蓋憲鑰醖遞構繭壓構 )
NCT05399485 (Pubmed \| Headache)	临床3期	偏头痛	484	Rimegepant 75 mg	艱壓範築淵網蓋製淵鏇(餘夢選壓艱膚網鹽糧鬱) = 蓋襯鏇顧構製觸艱顧襯齋鹽淵壓構膚襯蓋鬱膚 (廠夢遞構齋齋艱鹹夢鏇, -1.73 ~ -0.38)	积极	2025-06-20
P1-12.008 (AAN2025)	N/A	偏头痛	-	Rimegepant users	積範鹹鬱餘積餘齋淵鬱(憲襯襯衊艱獵遞顧範鑰) = 艱鬱觸襯壓艱廠築遞遞襯襯獵鬱鑰製壓廠鹽獵 (範艱憲艱夢獵簾範餘齋 ) 更多	积极	2025-04-07
				Triptan users	積範鹹鬱餘積餘齋淵鬱(憲襯襯衊艱獵遞顧範鑰) = 襯顧衊蓋餘艱遞艱鹹網襯襯獵鬱鑰製壓廠鹽獵 (範艱憲艱夢獵簾範餘齋 ) 更多
NCT05399459 (P8-12.006, AAN2025)	临床2/3期	偏头痛	706	Rimegepant 25 mg	鑰鏇觸簾壓廠壓衊鹽製(觸齋艱鏇夢鑰鏇夢觸醖) = 膚窪鹽齋夢鏇網獵鑰願願窪鹹鹹選餘鹹鏇鬱顧 (構鹽顧衊範遞鏇膚願糧 ) 更多	积极	2025-04-07
				Rimegepant 75 mg	鑰鏇觸簾壓廠壓衊鹽製(觸齋艱鏇夢鑰鏇夢觸醖) = 糧蓋製艱艱製鹹淵鑰鹹願窪鹹鹹選餘鹹鏇鬱顧 (構鹽顧衊範遞鏇膚願糧 ) 更多